Several indices of thyroid function were assessed in 74 patients with chronic renal failure. Sixty patients had undergone haemodialysis for varying periods. Within the first six months of haemodialysis treatment proteinbound iodine and total thyroxine (T4) levels rose, but after this T4 levels and the free thyroxine index fell progressively. Three out of the 12 patients who had undergone haemodialysis for longer than three years had subnormal T4 and supranormal thyrotrophin concentrations and a subnormal response to thyrotrophin stimulation. Long-term haemodialysis may be a cause of biochemical hypothyroidism.
Introduction
It has recently been shown that patients who have undergone haemodialysis for over a year have significantly lower serum thyroxine (T4) concentrations and significantly higher thryotrophin concentrations than those who have undergone haemodialysis for shorter periods. ' We have performed a more detailed study of thyroid function in 74 patients undergoing long-term haemodialysis.
Patients and methods
Seventy-five patients with chronic renal failure who were under observation and treatment at the renal unit in Sheffield were studied. They were divided into four groups.
Group 1 consisted of 13 patients who had had renal failure for at least six months but who were not on regular haemodialysis. They had creatinine clearances of 8-15 ml/min. Group 2 consisted of 18 patients who had been on dialysis for six months or less.
Group 3 consisted of 31 patients who had been undergoing haemodialysis for seven to 35 months.
Group 4 consisted of 12 patients who had been on regular haemodialysis for three years or more.
The patients in group 1 had a protein intake of 30 g/day, and all those on haemodialysis had an intake of 40 g/day. No patient was receiving steroids.
Protein-bound iodine (PBI), total serum thyroxine (T4), proteinbinding capacity (T3 resin uptake), and total serum triiodothyroxine (T3) were measured in all patients, and the free thyroxine index (FTI) was calculated. Thyrotrophin-releasing hormone (TRH) tests were carried out on 20 patients, only six of whom were in group 1 or 2. Thyrotrophin-stimulation tests were carried out by measuring serum PBI, T4, and protein-binding capacity before and 24 hours after the injection of 10 units of intramuscular thyrotrophin. PBI was measured by autoanalyser, and T3 and thyrotrophin were measured by immunoassay.
Results
Four of the 13 patients in group 1 had subnormal total T4 and PBI levels. Their serum albumin levels and protein-binding capacity were also subnormal, however, with the result that the FTI was normal in all patients in this group. Of the 18 patients in group 2 three had a low PBI level, two had subnormal T4, and only one (6%) had a subnormal FTI. In group 3 PBI, T4, and FTI were subnormal in three out of 31 patients, and in group 4 PBI, T4, and FTI were low in four out of 12 patients (tables I and II). 
Discussion
Our results show clearly that the incidence of abnormalities of thyroid function increases with the duration of haemodialysis. A third of the patients who had been on haemodialysis for over three years (group 4) had subnormal serum PBI and T4 levels, a low FTI, and raised thyrotrophin concentrations, while only one of the patients from group 2 and none from group 1 had a low FTI. T3 concentrations were subnormal in all patients in whom they were measured.
When the mean T4 and FTI values were considered similar trends were observed. thyrotrophin. In uraemic patients the degradation and removal of circulating thyrotrophin is diminished, which may account for the raised thyrotrophin levels. Cuttlelod et a14 also showed that thyrotrophin secretion rates were subnormal in uraemic patients in spite of the raised serum thyrotrophin levels. This explains the raised thyrotrophin concentrations, but it does not account for the fact that thyrotrophin was clearly raised in our patients with low normal or subnormal T4 levels but normal or high normal in those with normal T4 concentrations. This indicates that the integrity of the thyroid-pituitary feeedback mechanism is intact in these patients and that this feedback operates against a background of diminished thyrotrophin clearance from the circulation.
The TRH-induced thyrotrophin release was subnormal in all patients, there being no release at all in those patients who had clearly raised basal thyrotrophin concentrations. This is paradoxical in view of the low or low normal T4 concentrations observed in many of these patients. Cuttlelod et a14 also found subnormal responses to TRH in uraemic patients.
The diminution in the response of thyrotrophin to TRH might be the result of either a diminished thyrotrophin reserve in the thyrotroph or to an alternation in the excitability of the thyrotroph cell membrane. Gonzales et a15 observed that 200 jsg of TRH given intravenously induced no significant rise in serum thyrotrophin in uraemic patients, whereas an infusion of 800,ug did. This observation suggests that the thyrotrophs of uraemic patients have a raised threshold (or diminished excitability) to TRH. A raised threshold is indeed possible in view of the low protein intake of these patients. Rats maintained on low-protein diets have raised serum thyrotrophin concentrations associated with diminished thyrotrophin contents in their pituitary glands.6
These findings suggest a combined abnormality in the function of the thyroid and pituitary glands. The thyroid gland seems to be relatively insensitive to thyrotrophin, as indicated by low T4 levels and high thyrotrophin concentrations in the presence of a residual functional reserve (shown by the thyrotrophinstimulation test). Two patients also had a subnormal thyroid response. Higher than usual doses of TRH have been found to induce thyrotrophin release, which would suggest that the pituitary gland is relatively insensitive to TRH. At present we cannot comment on the possibility that there are diminished thyrotrophin stores in the pituitary glands of uraemic patients It is interesting that this report of an apparent increase in the incidence of biochemical hypothyroidism in patients on long-term haemodialysis should be from Sheffield, where many patients come from Derbyshire-an area renowned for goitre and the lack of iodide in tap water. A combination of leaching out of iodide from patients' blood during haemodialysis and the salt restriction (table salt is the main source of iodide) that these patients are subjected to probably results in progressive depletion of body iodide. Our findings are not entirely consistent with those observed in iodide deficiency, however. In this condition the ratio of T3 and T4 rises, whereas all our patients had subnormal T3 concentrations. Serum PBI levels were maintained in association with progressively diminishing serum T4 concentrations after haemodialysis, and the sensitivity of the thyroid gland to thyrotrophin was diminished, which would indicate that an intrinsic defect of thyroid hormone synthesis rather than iodide depletion underlay the thyroid function abnormality in these patients. Other factors like ionic abnormalities, chronic low protein intake, and the effect of uraemic toxins would also have to be considered to explain this abnormality. Carter et al7 have suggested that the subnormal T3 may be due to a diminished peripheral conversion of T4 to T3.
The clinical significance of these data is not entirely clear, especially since the patients with low T4 and raised thyrotrophin concentrations did not have symptoms specifically related to hypothyroidism. But marginal hypothyroidism is often extremely difficult to diagnose clinically. A study of ankle reflex durations in these patients is in progress to assess the presence of hypothyroidism at the end organs. A trial of treatment with iodine or thyroid hormones, or both, in patients who prove to be hypothyroid is also being considered.
Introduction
Clonidine is a hypotensive agent widely used to treat patients with high blood pressure.' The reported range of daily doses for optimum blood pressure control is 0-15-4-8 mg.2 When-used in conjunction with a diuretic, however, the maximum effective dose of clonidine may be considerably lower in many patients.3 In some patients small initial doses of clonidine have lowered blood pressure but when the dose has been increased the blood pressure has risen and become refractory to the drug.' We describe here two hypertensive patients whose blood pressures were apparently resistant to high doses of clonidine and the results of studies of both high and low doses of clonidine. Hg erect, and she was receiving clonidine 6 mg, propranolol 480 mg, and bendrofluazide 10 mg daily. Propranolol was withdrawn three days before the first clonidine study. After this study clonidine was withdrawn, and her blood pressure was controlled on labetalol 2-4 g and bendrofluazide 10 mg daily. Seven months later the second clonidine study was performed 16 hours after the last dose of labetalol.
Method
Each patient was investigated twice: once during long-term clonidine treatment and again seven to eight months after stopping clonidine. In the first study both patients received their usual morning dose of clonidine-1 8 mg (case 1) and 1-5 mg (case 2) orally. In the second they were given a single 0-3-mg dose of clonidine orally. Both patients gave their informed written consent to the procedures. The investigation was performed in a quiet clinical laboratory, where the
